CU Anschutz Called a Case Study for Commercializing Medical Breakthroughs miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in
Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
E-Mail
IMAGE: Lead study author Jordana Hoppe, MD, a pediatric pulmonologist with Children s Hospital Colorado and assistant professor of pediatrics at the University of Colorado School of Medicine on the Anschutz Medical. view more
Credit: Children s Hospital Colorado
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in
Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
Researchers to test a promising treatment for high-risk COVID-19 outpatients
The nation has been coping with the pandemic for more than a year, and in this time, researchers have learned a great deal about how to treat COVID-19. Yet they have also been faced with what they still must learn, including how to reach the individuals who have been most dramatically impacted by the disease and who could benefit the most from new treatments.
A new $8.7 million grant from the National Institutes of Health (NIH) will fuel these efforts for the next two years. Adit Ginde, MD, MPH, professor of emergency medicine at CU School of Medicine and UCHealth emergency physician is leading a team of researchers from the Colorado Clinical and Translational Sciences Institute at the University of Colorado Anschutz Medical Campus to test the real-world effectiveness of a promising treatment for high-risk COVID-19 outpatients.